Clinical Trial

Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study

Study acronym: FMT
Recruiting
View on ClinicalTrials.gov →
Summary
This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-06-12
critical Primary endpoint(s) modified 2026-06-12
notable Primary completion pushed: 2029-04-15 -> 2029-06-02 2026-06-12
minor Completion pushed: 2029-04-29 -> 2029-06-02 2026-06-12
Trial Details
NCT Number NCT07509450
Lead Sponsor University Health Network, Toronto
Conditions Lymphoma Receiving CAR-T Therapy
Enrollment 20 participants
Start Date 2026-06-02
Primary Completion 2029-06-02 (estimated)
Study Completion 2029-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-08